Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ixotatug vedotin

An antibody-drug conjugate (ADC) composed of ixotatug, a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6), linked to the auristatin derivative monomethyl auristatin E (MMAE) via a cleavable linker, with potential antineoplastic activity. Upon administration of ixotatug vedotin, the anti-CLDN6 antibody moiety targets and binds to CLDN6-expressing tumor cells. Upon binding, internalization, and linker cleavage, MMAE is released. MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. This induces cell death in CLDN6-expressing cancer cells. CLDN6, a transmembrane tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC TORL-1-23
Code name:TORL 1-23
TORL-1-23
TORL1-23
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search